Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 15;7(21):3716-3720.
doi: 10.3889/oamjms.2019.757. eCollection 2019 Nov 15.

The Prognostic Significance of Phosphatase and Tensin Homolog Loss in Breast Cancer

Affiliations

The Prognostic Significance of Phosphatase and Tensin Homolog Loss in Breast Cancer

Indri Windarti et al. Open Access Maced J Med Sci. .

Abstract

Aim: This study aims to determine the prognostic significance of phosphatase and tensin homolog (PTEN) loss in breast cancer.

Methods: We conducted a meta-analysis study. Sample of this study were research articles that evaluated PTEN loss and prognosis in breast cancer patients. We searched for relevant studies published in PubMed and Proquest from January 2010 to July 2018. We reviewed studies that examined the association between immunohistochemical expression of PTEN and breast cancer prognosis using meta-analysis methods. Pooled risk ratios (RR) were calculated using fixed and random-effect models. Data were processed using Review Manager 5.3 (RevMan 5.3).

Results: There were 7 studies conducted a systematic review then continued to evaluate the association of PTEN loss and breast cancer prognosis by meta-analysis. There was a significant association of PTEN loss with poor prognosis of breast cancer (RR = 0.76 [95% CI 0.59-0.98 p <0.07), and there was not any significant publication bias for studies included.

Conclusion: This study confirmed PTEN loss is an important independent factor for breast cancer prognosis.

Keywords: Breast cancer; Immunohistochemical; PTEN; Prognosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram research procedure
Figure 2
Figure 2
Forest plots the association of PTEN loss and breast cancer prognosis
Figure 3
Figure 3
Funnel plots the association of PTEN loss and breast cancer prognosis

Similar articles

Cited by

References

    1. Siegel RKM, Jemal A. Cancer Statistics 2015. CA Cancer J Clin. 2015;65(1):29–32. https://doi.org/10.3322/caac.21254 PMid:25559415. - PubMed
    1. International Agency for Research on Cancer. Globacon. 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012
    1. Youlden DR, Cramb SM, Cheng Har, Yip CH PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 2014;11(2):101–115. - PMC - PubMed
    1. Strasser-Weippi K, Horich N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, et al. Long-term hazard of recurrence in HER2+breast cancer patients untreated with antiHER2 therapy. Breast Cancer Res. 2015;17:56. https://doi.org/10.1186/s13058-015-0568-1 PMid:25888246 PMCid:PMC4423419. - PMC - PubMed
    1. Albayati MR, Alhilfi HS, Almohammadawi KO, Althaalibi SM, et al. An Outcome of Localized HER2 Positive Breast Cancer Treated with Adjuvant Trastuzumab in Clinical Practice:Retrospective Observational Study. Cancer Ther Oncol Int J. 2017;7(3):1–5. https://doi.org/10.19080/CTOIJ.2017.07.555712.

LinkOut - more resources